Identification

Name
Progesterone
Accession Number
DB00396  (APRD00700)
Type
Small Molecule
Groups
Approved, Vet Approved
Description

The major progestational steroid that is secreted primarily by the corpus luteum and the placenta. Progesterone acts on the uterus, the mammary glands, and the brain. It is required in embryo implantation, pregnancy maintenance, and the development of mammary tissue for milk production. Progesterone, converted from pregnenolone, also serves as an intermediate in the biosynthesis of gonadal steroid hormones and adrenal corticosteroids.

Structure
Thumb
Synonyms
  • (S)-4-Pregnene-3,20-dione
  • (S)-Pregn-4-en-3,20-dione
  • (S)-Progesterone
  • 17alpha-Progesterone
  • 17α-progesterone
  • 4-Pregnene-3,20-dione
  • Agolutin
  • Akrolutin
  • Corpus Luteum Hormone
  • delta(4)-Pregnene-3,20-dione
  • Gelbkörperhormon
  • Luteohormone
  • Lutogynon
  • Pregn-4-ene-3,20-dione
  • Progesteron
  • Progesterona
  • Progestérone
  • Progesterone
  • Progesteronum
External IDs
BP 14 / NSC-64377 / NSC-9704 / U 3672
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act Progesterone InjectionSolution50 mgIntramuscularActavis Pharma Company2016-04-13Not applicableCanada
CrinoneGel45 mg/1.125gVaginalColumbia Laboratories1997-05-13Not applicableUs
CrinoneGel45 mg/1.125gVaginalActavis Pharma Company1997-05-13Not applicableUs
CrinoneGel90 mg/1.125gVaginalActavis Pharma Company1997-05-13Not applicableUs
CrinoneGel8 %VaginalEmd Serono, A Division Of Emd Inc., Canada2000-05-20Not applicableCanada
CrinoneGel90 mg/1.125gVaginalActavis Pharma Company1997-05-13Not applicableUs
CrinoneGel90 mg/1.125gVaginalColumbia Laboratories1997-05-13Not applicableUs
CrinoneGel90 mg/1.125gVaginalColumbia Laboratories1997-05-13Not applicableUs
CrinoneGel45 mg/1.125gVaginalActavis Pharma Company1997-05-13Not applicableUs
EndometrinInsert100 mg/1VaginalFerring Pharmaceuticals2007-06-21Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ProgesteroneCapsule200 mg/1OralAv Kare, Inc.2013-06-042015-12-29Us
ProgesteroneCapsule100 mg/1OralAmneal Pharmaceuticals2017-09-11Not applicableUs
ProgesteroneInjection50 mg/1IntramuscularWest Ward Pharmaceutical2010-10-28Not applicableUs
ProgesteroneCapsule100 mg/1OralA S Medication Solutions2015-10-012017-06-20Us
ProgesteroneCapsule200 mg/1OralBanner Pharmacaps2014-01-01Not applicableUs
ProgesteroneCapsule100 mg/1OralGolden State Medical Supply2014-04-232017-10-26Us
ProgesteroneCapsule100 mg/1OralA S Medication Solutions2012-10-042017-06-20Us
ProgesteroneCapsule100 mg/1OralA S Medication Solutions2014-01-012017-06-20Us
ProgesteroneCapsule, liquid filled200 mg/1OralTeva2012-03-01Not applicableUs00093 5354 01 nlmimage10 e73673e3
ProgesteroneCapsule200 mg/1OralBanner Life Sciences Llc.2015-10-01Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ProgesteroneCapsule100 mg/1OralPd Rx Pharmaceuticals, Inc.2010-07-302018-04-30Us
International/Other Brands
Agolutin (Biotika) / Crinone / Cyclogest (Actavis) / Gesterol / Gestone (Nordic Pharma) / Progestasert / Progestogel (Besins) / Qi Ning (Aisheng Pharmaceutical) / Relantan (Aversi) / Susten (Sun Pharma) / Utrogestan (Besins) / Utrogestran (Faran Laboratories) / Utrovin (Bestochem) / Vasclor (Verisfield)
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Estrogel PropakProgesterone (100 mg) + Estradiol (0.06 %)Capsule; Gel, meteredOral; TransdermalMerck Ltd.2013-04-082016-06-08Canada
Categories
UNII
4G7DS2Q64Y
CAS number
57-83-0
Weight
Average: 314.4617
Monoisotopic: 314.224580204
Chemical Formula
C21H30O2
InChI Key
RJKFOVLPORLFTN-LEKSSAKUSA-N
InChI
InChI=1S/C21H30O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h12,16-19H,4-11H2,1-3H3/t16-,17+,18-,19-,20-,21+/m0/s1
IUPAC Name
(1S,3aS,3bS,9aR,9bS,11aS)-1-acetyl-9a,11a-dimethyl-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-7-one
SMILES

Pharmacology

Indication

For progesterone supplementation or replacement as part of an Assisted Reproductive Technology (ART) treatment for infertile women with progesterone deficiency and for the treatment of secondary amenorrhea. Also used for the reduction of the incidence of endometrial hyperplasia and the attendant risk of endometrial carcinoma in postmenopausal women receiving estrogen replacement therapy, as well as treatment of abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology such as fibroids or uterine cancer.

Structured Indications
Pharmacodynamics

Progesterone is a naturally occuring progestin or a synthetic form of the naturally occurring female sex hormone, progesterone. In a woman's normal menstrual cycle, an egg matures and is released from the ovaries (ovulation). The ovary then produces progesterone, preventing the release of further eggs and priming the lining of the womb for a possible pregnancy. If pregnancy occurs, progesterone levels in the body remain high, maintaining the womb lining. If pregnancy does not occur, progesterone levels in the body fall, resulting in a menstrual period. Progesterone tricks the body processes into thinking that ovulation has already occurred by maintaining high levels of the synthetic progesterone. This prevents the release of eggs from the ovaries.

Mechanism of action

Progesterone shares the pharmacological actions of the progestins. Progesterone binds to the progesterone and estrogen receptors. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Once bound to the receptor, progestins like Progesterone will slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH (luteinizing hormone) surge. In women who have adequate endogenous estrogen, progesterone transforms a proliferative endometrium into a secretory one. Progesterone is essential for the development of decidual tissue and is necessary to increase endometrial receptivity for implantation of an embryo. Once an embryo has been implanted, progesterone acts to maintain the pregnancy. Progesterone also stimulates the growth of mammary alveolar tissue and relaxes uterine smooth muscle. It has little estrogenic and androgenic activity.

TargetActionsOrganism
AProgesterone receptor
agonist
Human
AEstrogen receptor alpha
agonist
Human
AMineralocorticoid receptor
antagonist
Human
USteroid 17-alpha-hydroxylase/17,20 lyase
inhibitor
Human
UKappa-type opioid receptor
activator
Human
UNuclear receptor subfamily 1 group I member 2Not AvailableHuman
UAlpha-1-acid glycoprotein 1Not AvailableHuman
UGlucocorticoid receptor
partial agonist
Human
UAndrogen receptorNot AvailableHuman
USex hormone-binding globulinNot AvailableHuman
Absorption

Progesterone absorption is prolonged with an absorption half-life of approximately 25-50 hours.

Volume of distribution
Not Available
Protein binding

96%-99%

Metabolism

Progesterone is metabolized primarily by the liver largely to pregnanediols and pregnanolones.

Route of elimination

The glucuronide and sulfate conjugates of pregnanediol and pregnanolone are excreted in the urine and bile. Progesterone metabolites which are excreted in the bile may undergo enterohepatic recycling or may be excreted in the feces. Progesterone metabolites are excreted mainly by the kidneys.

Half life

34.8-55.13 hours

Clearance
  • 2510 +/- 135 L/day [cycling women]
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
17-alpha-hydroxylase deficiency (CYP17)Disease
Corticosterone methyl oxidase I deficiency (CMO I)Disease
SteroidogenesisMetabolic
Adrenal Hyperplasia Type 3 or Congenital Adrenal Hyperplasia due to 21-hydroxylase DeficiencyDisease
21-hydroxylase deficiency (CYP21)Disease
Apparent mineralocorticoid excess syndromeDisease
3-Beta-Hydroxysteroid Dehydrogenase DeficiencyDisease
Congenital Lipoid Adrenal Hyperplasia (CLAH) or Lipoid CAHDisease
Adrenal Hyperplasia Type 5 or Congenital Adrenal Hyperplasia due to 17 Alpha-hydroxylase DeficiencyDisease
11-beta-hydroxylase deficiency (CYP11B1)Disease
Corticosterone methyl oxidase II deficiency - CMO IIDisease
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe therapeutic efficacy of Progesterone can be decreased when used in combination with 2-HYDROXY-1,4-NAPHTHOQUINONE.Experimental
2-mercaptobenzothiazoleThe therapeutic efficacy of Progesterone can be decreased when used in combination with 2-mercaptobenzothiazole.Vet Approved
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Progesterone.Investigational
AbciximabThe therapeutic efficacy of Abciximab can be decreased when used in combination with Progesterone.Approved
AbirateroneThe serum concentration of Progesterone can be increased when it is combined with Abiraterone.Approved
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Progesterone.Approved, Investigational
AcenocoumarolThe therapeutic efficacy of Acenocoumarol can be decreased when used in combination with Progesterone.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Progesterone.Investigational, Withdrawn
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Progesterone.Approved
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Progesterone.Experimental, Investigational
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Progesterone.Investigational
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Progesterone.Approved
AmiodaroneThe metabolism of Progesterone can be decreased when combined with Amiodarone.Approved, Investigational
AmorolfineThe therapeutic efficacy of Progesterone can be decreased when used in combination with Amorolfine.Approved, Investigational
Amphotericin BThe therapeutic efficacy of Progesterone can be decreased when used in combination with Amphotericin B.Approved, Investigational
AncrodThe therapeutic efficacy of Ancrod can be decreased when used in combination with Progesterone.Investigational
AnidulafunginThe therapeutic efficacy of Progesterone can be decreased when used in combination with Anidulafungin.Approved, Investigational
Antithrombin III humanThe therapeutic efficacy of Antithrombin III human can be decreased when used in combination with Progesterone.Approved
ApixabanThe therapeutic efficacy of Apixaban can be decreased when used in combination with Progesterone.Approved
AprepitantThe serum concentration of Progesterone can be increased when it is combined with Aprepitant.Approved, Investigational
ArdeparinThe therapeutic efficacy of Ardeparin can be decreased when used in combination with Progesterone.Approved, Investigational, Withdrawn
ArgatrobanThe therapeutic efficacy of Argatroban can be decreased when used in combination with Progesterone.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Progesterone.Approved, Investigational
ArmodafinilThe metabolism of Progesterone can be decreased when combined with Armodafinil.Approved, Investigational
ArtemetherThe therapeutic efficacy of Progesterone can be decreased when used in combination with Artemether.Approved
AtazanavirThe metabolism of Progesterone can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Progesterone can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Progesterone is combined with Atorvastatin.Approved
AzithromycinThe metabolism of Progesterone can be decreased when combined with Azithromycin.Approved
Bafilomycin A1The therapeutic efficacy of Progesterone can be decreased when used in combination with Bafilomycin A1.Experimental
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Progesterone.Investigational
BecaplerminThe therapeutic efficacy of Becaplermin can be decreased when used in combination with Progesterone.Approved, Investigational
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Progesterone.Investigational
Benzoic AcidThe therapeutic efficacy of Progesterone can be decreased when used in combination with Benzoic Acid.Approved
BetaxololThe metabolism of Progesterone can be decreased when combined with Betaxolol.Approved
BifonazoleThe therapeutic efficacy of Progesterone can be decreased when used in combination with Bifonazole.Approved, Investigational
BivalirudinThe therapeutic efficacy of Bivalirudin can be decreased when used in combination with Progesterone.Approved, Investigational
BoceprevirThe metabolism of Progesterone can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Progesterone can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Progesterone can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Progesterone.Approved
Brefeldin AThe therapeutic efficacy of Progesterone can be decreased when used in combination with Brefeldin A.Experimental
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Progesterone.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Progesterone.Approved, Investigational
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Progesterone.Investigational, Withdrawn
BupropionThe metabolism of Progesterone can be decreased when combined with Bupropion.Approved
ButenafineThe therapeutic efficacy of Progesterone can be decreased when used in combination with Butenafine.Approved
ButoconazoleThe therapeutic efficacy of Progesterone can be decreased when used in combination with Butoconazole.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Progesterone.Approved
CaffeineThe metabolism of Progesterone can be decreased when combined with Caffeine.Approved
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Progesterone.Approved
CandicidinThe therapeutic efficacy of Progesterone can be decreased when used in combination with Candicidin.Withdrawn
CapecitabineThe metabolism of Progesterone can be decreased when combined with Capecitabine.Approved, Investigational
Capric acidThe therapeutic efficacy of Progesterone can be decreased when used in combination with Capric acid.Experimental
CarbamazepineThe metabolism of Progesterone can be increased when combined with Carbamazepine.Approved, Investigational
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Progesterone.Experimental
CaspofunginThe therapeutic efficacy of Progesterone can be decreased when used in combination with Caspofungin.Approved
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Progesterone.Experimental
CelecoxibThe metabolism of Progesterone can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Progesterone can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Progesterone.Withdrawn
CertoparinThe therapeutic efficacy of Certoparin can be decreased when used in combination with Progesterone.Approved, Investigational
CeruleninThe therapeutic efficacy of Progesterone can be decreased when used in combination with Cerulenin.Approved
ChloramphenicolThe metabolism of Progesterone can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChloroquineThe metabolism of Progesterone can be decreased when combined with Chloroquine.Approved, Vet Approved
ChloroxineThe therapeutic efficacy of Progesterone can be decreased when used in combination with Chloroxine.Approved
ChlorpromazineThe metabolism of Progesterone can be decreased when combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Progesterone.Approved
CholecalciferolThe metabolism of Progesterone can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
Cholic AcidProgesterone may decrease the excretion rate of Cholic Acid which could result in a higher serum level.Approved
CiclopiroxThe therapeutic efficacy of Progesterone can be decreased when used in combination with Ciclopirox.Approved, Investigational
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Progesterone.Experimental
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Progesterone.Approved
CimetidineThe metabolism of Progesterone can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Progesterone can be decreased when combined with Cinacalcet.Approved
CitalopramThe metabolism of Progesterone can be decreased when combined with Citalopram.Approved
Citric AcidThe therapeutic efficacy of Citric Acid can be decreased when used in combination with Progesterone.Approved, Nutraceutical, Vet Approved
ClarithromycinThe metabolism of Progesterone can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Progesterone can be decreased when combined with Clemastine.Approved
ClobazamThe metabolism of Progesterone can be decreased when combined with Clobazam.Approved, Illicit
ClomipramineThe metabolism of Progesterone can be decreased when combined with Clomipramine.Approved, Vet Approved
ClotrimazoleThe therapeutic efficacy of Progesterone can be decreased when used in combination with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Progesterone can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Progesterone can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Progesterone can be decreased when combined with Cocaine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Progesterone.Approved
Conestat alfaProgesterone may increase the thrombogenic activities of Conestat alfa.Approved
ConivaptanThe serum concentration of Progesterone can be increased when it is combined with Conivaptan.Approved, Investigational
CordycepinThe therapeutic efficacy of Progesterone can be decreased when used in combination with Cordycepin.Investigational
CrisaboroleThe metabolism of Progesterone can be decreased when combined with Crisaborole.Approved
CrizotinibThe metabolism of Progesterone can be decreased when combined with Crizotinib.Approved
CyclosporineThe therapeutic efficacy of Progesterone can be decreased when used in combination with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Progesterone can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Progesterone.Approved
DabrafenibThe serum concentration of Progesterone can be decreased when it is combined with Dabrafenib.Approved
DalteparinThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Progesterone.Approved
DanaparoidThe therapeutic efficacy of Danaparoid can be decreased when used in combination with Progesterone.Approved, Withdrawn
DarexabanThe therapeutic efficacy of Darexaban can be decreased when used in combination with Progesterone.Investigational
DarifenacinThe metabolism of Progesterone can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Progesterone can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Progesterone can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Progesterone can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Progesterone can be decreased when combined with Delavirdine.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Progesterone.Investigational
DesipramineThe metabolism of Progesterone can be decreased when combined with Desipramine.Approved
DesirudinThe therapeutic efficacy of Desirudin can be decreased when used in combination with Progesterone.Approved
DextranThe therapeutic efficacy of Dextran can be decreased when used in combination with Progesterone.Approved, Vet Approved
Dextran 40The therapeutic efficacy of Dextran 40 can be decreased when used in combination with Progesterone.Approved
Dextran 70The therapeutic efficacy of Dextran 70 can be decreased when used in combination with Progesterone.Approved
Dextran 75The therapeutic efficacy of Dextran 75 can be decreased when used in combination with Progesterone.Approved
DichloropheneThe therapeutic efficacy of Progesterone can be decreased when used in combination with Dichlorophene.Vet Approved
DicoumarolThe therapeutic efficacy of Dicoumarol can be decreased when used in combination with Progesterone.Approved
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Progesterone.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Progesterone.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Progesterone.Experimental
DihydroergotamineThe metabolism of Progesterone can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Progesterone can be decreased when combined with Diltiazem.Approved
DiphenhydramineThe metabolism of Progesterone can be decreased when combined with Diphenhydramine.Approved
DosulepinThe metabolism of Progesterone can be decreased when combined with Dosulepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Progesterone.Approved, Investigational
DoxycyclineThe metabolism of Progesterone can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Progesterone can be decreased when combined with Dronedarone.Approved
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Progesterone.Approved
DuloxetineThe metabolism of Progesterone can be decreased when combined with Duloxetine.Approved
EconazoleThe therapeutic efficacy of Progesterone can be decreased when used in combination with Econazole.Approved
Edetic AcidThe therapeutic efficacy of Edetic Acid can be decreased when used in combination with Progesterone.Approved, Vet Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Progesterone.Approved
EfavirenzThe metabolism of Progesterone can be decreased when combined with Efavirenz.Approved, Investigational
EfinaconazoleThe therapeutic efficacy of Progesterone can be decreased when used in combination with Efinaconazole.Approved
EliglustatThe metabolism of Progesterone can be decreased when combined with Eliglustat.Approved
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Progesterone.Approved
EnoxaparinThe therapeutic efficacy of Enoxaparin can be decreased when used in combination with Progesterone.Approved
EnzalutamideThe serum concentration of Progesterone can be decreased when it is combined with Enzalutamide.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Progesterone.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Progesterone.Approved
ErythromycinThe metabolism of Progesterone can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe metabolism of Progesterone can be decreased when combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe metabolism of Progesterone can be decreased when combined with Esomeprazole.Approved, Investigational
Ethyl biscoumacetateThe therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Progesterone.Withdrawn
EtravirineThe metabolism of Progesterone can be decreased when combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Progesterone.Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Progesterone.Approved, Investigational
FelodipineThe metabolism of Progesterone can be decreased when combined with Felodipine.Approved, Investigational
FenticonazoleThe therapeutic efficacy of Progesterone can be decreased when used in combination with Fenticonazole.Experimental
Ferulic acidThe therapeutic efficacy of Ferulic acid can be decreased when used in combination with Progesterone.Experimental
FloxuridineThe metabolism of Progesterone can be decreased when combined with Floxuridine.Approved
FluconazoleThe therapeutic efficacy of Progesterone can be decreased when used in combination with Fluconazole.Approved
FlucytosineThe therapeutic efficacy of Progesterone can be decreased when used in combination with Flucytosine.Approved
FluindioneThe therapeutic efficacy of Fluindione can be decreased when used in combination with Progesterone.Investigational
FluorouracilThe metabolism of Progesterone can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Progesterone can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlutrimazoleThe therapeutic efficacy of Progesterone can be decreased when used in combination with Flutrimazole.Experimental
FluvastatinThe metabolism of Progesterone can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Progesterone can be decreased when combined with Fluvoxamine.Approved, Investigational
FondaparinuxThe therapeutic efficacy of Fondaparinux can be decreased when used in combination with Progesterone.Investigational
Fondaparinux sodiumThe therapeutic efficacy of Fondaparinux sodium can be decreased when used in combination with Progesterone.Approved, Investigational
FosamprenavirThe metabolism of Progesterone can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Progesterone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Progesterone can be increased when combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Progesterone can be increased when it is combined with Fusidic Acid.Approved
GabexateThe therapeutic efficacy of Gabexate can be decreased when used in combination with Progesterone.Investigational
GemfibrozilThe metabolism of Progesterone can be decreased when combined with Gemfibrozil.Approved
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Progesterone.Investigational, Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Progesterone.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Progesterone.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Progesterone.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Progesterone.Approved, Investigational
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Progesterone.Approved
GlyphosateThe therapeutic efficacy of Progesterone can be decreased when used in combination with Glyphosate.Experimental
GriseofulvinThe therapeutic efficacy of Progesterone can be decreased when used in combination with Griseofulvin.Approved, Vet Approved
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Progesterone.Investigational
HachimycinThe therapeutic efficacy of Progesterone can be decreased when used in combination with Hachimycin.Experimental
HaloperidolThe metabolism of Progesterone can be decreased when combined with Haloperidol.Approved
HaloproginThe therapeutic efficacy of Progesterone can be decreased when used in combination with Haloprogin.Approved, Withdrawn
HeparinThe therapeutic efficacy of Heparin can be decreased when used in combination with Progesterone.Approved, Investigational
HexetidineThe therapeutic efficacy of Progesterone can be decreased when used in combination with Hexetidine.Approved, Investigational
Human C1-esterase inhibitorProgesterone may increase the thrombogenic activities of Human C1-esterase inhibitor.Approved
IdelalisibThe serum concentration of Progesterone can be increased when it is combined with Idelalisib.Approved
IdraparinuxThe therapeutic efficacy of Idraparinux can be decreased when used in combination with Progesterone.Investigational
ImatinibThe metabolism of Progesterone can be decreased when combined with Imatinib.Approved
ImipramineThe metabolism of Progesterone can be decreased when combined with Imipramine.Approved
IndinavirThe metabolism of Progesterone can be decreased when combined with Indinavir.Approved
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Progesterone.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Progesterone.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Progesterone.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Progesterone.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Progesterone.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Progesterone.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Progesterone.Approved
IrbesartanThe metabolism of Progesterone can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Progesterone can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoconazoleThe therapeutic efficacy of Progesterone can be decreased when used in combination with Isoconazole.Approved
IsoniazidThe metabolism of Progesterone can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Progesterone can be decreased when combined with Isradipine.Approved
ItraconazoleThe therapeutic efficacy of Progesterone can be decreased when used in combination with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Progesterone can be increased when it is combined with Ivacaftor.Approved
KetoconazoleThe therapeutic efficacy of Progesterone can be decreased when used in combination with Ketoconazole.Approved, Investigational
LapatinibThe metabolism of Progesterone can be decreased when combined with Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Progesterone.Approved
LeflunomideThe metabolism of Progesterone can be decreased when combined with Leflunomide.Approved, Investigational
LepirudinThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Progesterone.Approved
LetaxabanThe therapeutic efficacy of Letaxaban can be decreased when used in combination with Progesterone.Investigational
LidocaineThe metabolism of Progesterone can be decreased when combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Progesterone.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Progesterone.Approved
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Progesterone.Approved, Investigational
LobeglitazoneThe metabolism of Progesterone can be decreased when combined with Lobeglitazone.Approved, Investigational
LopinavirThe metabolism of Progesterone can be decreased when combined with Lopinavir.Approved
LorcaserinThe metabolism of Progesterone can be decreased when combined with Lorcaserin.Approved
LosartanThe metabolism of Progesterone can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Progesterone can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Progesterone can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Progesterone can be increased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Progesterone can be decreased when combined with Lumefantrine.Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Progesterone.Illicit, Investigational, Withdrawn
ManidipineThe metabolism of Progesterone can be decreased when combined with Manidipine.Approved, Investigational
MelagatranThe therapeutic efficacy of Melagatran can be decreased when used in combination with Progesterone.Experimental
MepartricinThe therapeutic efficacy of Progesterone can be decreased when used in combination with Mepartricin.Experimental
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Progesterone.Experimental
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Progesterone.Approved
MethadoneThe metabolism of Progesterone can be decreased when combined with Methadone.Approved
MethotrimeprazineThe metabolism of Progesterone can be decreased when combined with Methotrimeprazine.Approved
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Progesterone.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Progesterone.Approved
MetoprololThe metabolism of Progesterone can be decreased when combined with Metoprolol.Approved, Investigational
MevastatinThe therapeutic efficacy of Progesterone can be decreased when used in combination with Mevastatin.Experimental
MexiletineThe metabolism of Progesterone can be decreased when combined with Mexiletine.Approved
MicafunginThe therapeutic efficacy of Progesterone can be decreased when used in combination with Micafungin.Approved, Investigational
MiconazoleThe therapeutic efficacy of Progesterone can be decreased when used in combination with Miconazole.Approved, Investigational, Vet Approved
MidostaurinThe metabolism of Progesterone can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Progesterone can be increased when it is combined with Mifepristone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Progesterone.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Progesterone.Approved
MiltefosineThe therapeutic efficacy of Progesterone can be decreased when used in combination with Miltefosine.Approved
MirabegronThe metabolism of Progesterone can be decreased when combined with Mirabegron.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Progesterone.Approved, Investigational
MitotaneThe serum concentration of Progesterone can be decreased when it is combined with Mitotane.Approved
MoclobemideThe metabolism of Progesterone can be decreased when combined with Moclobemide.Approved
ModafinilThe metabolism of Progesterone can be decreased when combined with Modafinil.Approved, Investigational
MonensinThe therapeutic efficacy of Progesterone can be decreased when used in combination with Monensin.Vet Approved
MyxothiazolThe therapeutic efficacy of Progesterone can be decreased when used in combination with Myxothiazol.Experimental
NadroparinThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Progesterone.Approved
NafamostatThe therapeutic efficacy of Nafamostat can be decreased when used in combination with Progesterone.Approved, Investigational
NaftifineThe therapeutic efficacy of Progesterone can be decreased when used in combination with Naftifine.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Progesterone.Approved
NatamycinThe therapeutic efficacy of Progesterone can be decreased when used in combination with Natamycin.Approved
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Progesterone.Approved, Investigational
NefazodoneThe metabolism of Progesterone can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Progesterone can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Progesterone can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Progesterone can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Progesterone can be decreased when combined with Nicardipine.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Progesterone.Approved, Investigational
NicotineThe metabolism of Progesterone can be decreased when combined with Nicotine.Approved
NifuratelThe therapeutic efficacy of Progesterone can be decreased when used in combination with Nifuratel.Experimental
Nikkomycin ZThe therapeutic efficacy of Progesterone can be decreased when used in combination with Nikkomycin Z.Investigational
NilotinibThe metabolism of Progesterone can be decreased when combined with Nilotinib.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Progesterone.Approved
NitroxolineThe therapeutic efficacy of Progesterone can be decreased when used in combination with Nitroxoline.Approved
NystatinThe therapeutic efficacy of Progesterone can be decreased when used in combination with Nystatin.Approved, Vet Approved
OlaparibThe metabolism of Progesterone can be decreased when combined with Olaparib.Approved
OmeprazoleThe metabolism of Progesterone can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OmoconazoleThe therapeutic efficacy of Progesterone can be decreased when used in combination with Omoconazole.Experimental
OsimertinibThe serum concentration of Progesterone can be increased when it is combined with Osimertinib.Approved
OtamixabanThe therapeutic efficacy of Otamixaban can be decreased when used in combination with Progesterone.Investigational
OxiconazoleThe therapeutic efficacy of Progesterone can be decreased when used in combination with Oxiconazole.Approved
pafuramidineThe therapeutic efficacy of Progesterone can be decreased when used in combination with pafuramidine.Investigational
PalbociclibThe serum concentration of Progesterone can be increased when it is combined with Palbociclib.Approved
PanobinostatThe serum concentration of Progesterone can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Progesterone can be decreased when combined with Pantoprazole.Approved
ParoxetineThe metabolism of Progesterone can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Progesterone.Approved
Peginterferon alfa-2bThe serum concentration of Progesterone can be decreased when it is combined with Peginterferon alfa-2b.Approved
Pentaerythritol TetranitrateThe therapeutic efficacy of Pentaerythritol Tetranitrate can be decreased when used in combination with Progesterone.Approved
PentamidineThe therapeutic efficacy of Progesterone can be decreased when used in combination with Pentamidine.Approved
PentobarbitalThe metabolism of Progesterone can be increased when combined with Pentobarbital.Approved, Vet Approved
Pentosan PolysulfateThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Progesterone.Approved
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Progesterone.Approved, Investigational, Vet Approved, Withdrawn
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Progesterone.Approved, Investigational, Withdrawn
PhenindioneThe therapeutic efficacy of Phenindione can be decreased when used in combination with Progesterone.Approved, Investigational
PhenobarbitalThe metabolism of Progesterone can be increased when combined with Phenobarbital.Approved
PhenprocoumonThe therapeutic efficacy of Phenprocoumon can be decreased when used in combination with Progesterone.Approved, Investigational
PhenytoinThe metabolism of Progesterone can be increased when combined with Phenytoin.Approved, Vet Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Progesterone.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Progesterone.Approved
PosaconazoleThe therapeutic efficacy of Progesterone can be decreased when used in combination with Posaconazole.Approved, Investigational, Vet Approved
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Progesterone.Approved, Investigational
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Progesterone.Approved
PrimidoneThe metabolism of Progesterone can be increased when combined with Primidone.Approved, Vet Approved
PromazineThe metabolism of Progesterone can be decreased when combined with Promazine.Approved, Vet Approved
Protein CThe therapeutic efficacy of Protein C can be decreased when used in combination with Progesterone.Approved
Protein S humanThe therapeutic efficacy of Protein S human can be decreased when used in combination with Progesterone.Approved
ProtocatechualdehydeThe therapeutic efficacy of Protocatechualdehyde can be decreased when used in combination with Progesterone.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Progesterone.Approved
PyrimethamineThe metabolism of Progesterone can be decreased when combined with Pyrimethamine.Approved, Vet Approved
PyrrolnitrinThe therapeutic efficacy of Progesterone can be decreased when used in combination with Pyrrolnitrin.Experimental
QuinidineThe metabolism of Progesterone can be decreased when combined with Quinidine.Approved
QuinineThe metabolism of Progesterone can be decreased when combined with Quinine.Approved
RabeprazoleThe metabolism of Progesterone can be decreased when combined with Rabeprazole.Approved, Investigational
RadicicolThe therapeutic efficacy of Progesterone can be decreased when used in combination with Radicicol.Experimental
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Progesterone.Approved, Investigational
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Progesterone.Approved, Investigational
ReviparinThe therapeutic efficacy of Reviparin can be decreased when used in combination with Progesterone.Approved, Investigational
RifabutinThe metabolism of Progesterone can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Progesterone can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Progesterone can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Progesterone.Approved, Investigational
RitonavirThe metabolism of Progesterone can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Progesterone.Approved
RolapitantThe metabolism of Progesterone can be decreased when combined with Rolapitant.Approved
RopiniroleThe metabolism of Progesterone can be decreased when combined with Ropinirole.Approved, Investigational
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Progesterone.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Progesterone.Approved
Salicylhydroxamic AcidThe therapeutic efficacy of Progesterone can be decreased when used in combination with Salicylhydroxamic Acid.Experimental
Salicylic acidThe therapeutic efficacy of Progesterone can be decreased when used in combination with Salicylic acid.Approved, Vet Approved
SaquinavirThe metabolism of Progesterone can be decreased when combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Progesterone.Approved
SecobarbitalThe metabolism of Progesterone can be increased when combined with Secobarbital.Approved, Vet Approved
SertaconazoleThe therapeutic efficacy of Progesterone can be decreased when used in combination with Sertaconazole.Approved
SertralineThe metabolism of Progesterone can be decreased when combined with Sertraline.Approved
SildenafilThe metabolism of Progesterone can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Progesterone.Approved
SiltuximabThe serum concentration of Progesterone can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Progesterone can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Progesterone.Approved
SinefunginThe therapeutic efficacy of Progesterone can be decreased when used in combination with Sinefungin.Experimental
SirolimusThe therapeutic efficacy of Progesterone can be decreased when used in combination with Sirolimus.Approved, Investigational
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Progesterone.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Progesterone.Approved
SorafenibThe metabolism of Progesterone can be decreased when combined with Sorafenib.Approved, Investigational
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Progesterone.Investigational
St. John's WortThe serum concentration of Progesterone can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Progesterone can be increased when it is combined with Stiripentol.Approved
SulconazoleThe therapeutic efficacy of Progesterone can be decreased when used in combination with Sulconazole.Approved
SulfadiazineThe metabolism of Progesterone can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Progesterone can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Progesterone can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Progesterone.Approved, Investigational
TamoxifenThe metabolism of Progesterone can be decreased when combined with Tamoxifen.Approved
TavaboroleThe therapeutic efficacy of Progesterone can be decreased when used in combination with Tavaborole.Approved
TelaprevirThe metabolism of Progesterone can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Progesterone can be decreased when combined with Telithromycin.Approved
Tenofovir disoproxilThe metabolism of Progesterone can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TerbinafineThe therapeutic efficacy of Progesterone can be decreased when used in combination with Terbinafine.Approved, Investigational, Vet Approved
TerconazoleThe therapeutic efficacy of Progesterone can be decreased when used in combination with Terconazole.Approved
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Progesterone.Experimental
TeriflunomideThe serum concentration of Progesterone can be decreased when it is combined with Teriflunomide.Approved
TheophyllineThe metabolism of Progesterone can be decreased when combined with Theophylline.Approved
ThioridazineThe metabolism of Progesterone can be decreased when combined with Thioridazine.Approved, Withdrawn
ThymolThe therapeutic efficacy of Progesterone can be decreased when used in combination with Thymol.Approved
TicagrelorThe metabolism of Progesterone can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Progesterone can be decreased when combined with Ticlopidine.Approved
TioconazoleThe therapeutic efficacy of Progesterone can be decreased when used in combination with Tioconazole.Approved
TipranavirThe metabolism of Progesterone can be decreased when combined with Tipranavir.Approved, Investigational
TocilizumabThe serum concentration of Progesterone can be decreased when it is combined with Tocilizumab.Approved
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Progesterone.Approved
TolbutamideThe metabolism of Progesterone can be decreased when combined with Tolbutamide.Approved
TolciclateThe therapeutic efficacy of Progesterone can be decreased when used in combination with Tolciclate.Experimental
TolnaftateThe therapeutic efficacy of Progesterone can be decreased when used in combination with Tolnaftate.Approved, Vet Approved
TopiramateThe metabolism of Progesterone can be decreased when combined with Topiramate.Approved
TopiroxostatThe metabolism of Progesterone can be decreased when combined with Topiroxostat.Approved, Investigational
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Progesterone.Approved, Investigational
TranylcypromineThe metabolism of Progesterone can be decreased when combined with Tranylcypromine.Approved
TrimethoprimThe metabolism of Progesterone can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrimetrexateThe therapeutic efficacy of Progesterone can be decreased when used in combination with Trimetrexate.Approved, Investigational
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Progesterone.Investigational, Withdrawn
TroxerutinThe therapeutic efficacy of Troxerutin can be decreased when used in combination with Progesterone.Investigational
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Progesterone.Approved, Experimental
UlipristalThe therapeutic efficacy of Progesterone can be decreased when used in combination with Ulipristal.Approved
Valproic AcidThe metabolism of Progesterone can be decreased when combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Progesterone can be decreased when combined with Valsartan.Approved, Investigational
VemurafenibThe serum concentration of Progesterone can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Progesterone can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Progesterone can be decreased when combined with Verapamil.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Progesterone.Approved, Investigational
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Progesterone.Approved, Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Progesterone.Approved, Investigational
VoriconazoleThe therapeutic efficacy of Progesterone can be decreased when used in combination with Voriconazole.Approved, Investigational
WarfarinThe therapeutic efficacy of Warfarin can be decreased when used in combination with Progesterone.Approved
XimelagatranThe therapeutic efficacy of Ximelagatran can be decreased when used in combination with Progesterone.Approved, Investigational, Withdrawn
ZafirlukastThe metabolism of Progesterone can be decreased when combined with Zafirlukast.Approved, Investigational
ZiprasidoneThe metabolism of Progesterone can be decreased when combined with Ziprasidone.Approved
ZucapsaicinThe metabolism of Progesterone can be decreased when combined with Zucapsaicin.Approved
Food Interactions
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (Caffeine).
  • Increase dietary intake of magnesium, folate, vitamin B6, B12, and/or consider taking a multivitamin.
  • Take at the same time everyday.
  • Take with food.

References

Synthesis Reference

Nejib M. Nasraoui, Alain Piasco, "Derivatives of 19-nor progesterone; process for producing them and the pharmaceutical compositions incorporating them." U.S. Patent US5223492, issued May, 1971.

US5223492
General References
  1. Allen WM: THE ISOLATION OF CRYSTALLINE PROGESTIN. Science. 1935 Aug 2;82(2118):89-93. [PubMed:17747122]
  2. Allen WM: Progesterone: how did the name originate? South Med J. 1970 Oct;63(10):1151-5. [PubMed:4922128]
  3. Schumacher M, Guennoun R, Robert F, Carelli C, Gago N, Ghoumari A, Gonzalez Deniselle MC, Gonzalez SL, Ibanez C, Labombarda F, Coirini H, Baulieu EE, De Nicola AF: Local synthesis and dual actions of progesterone in the nervous system: neuroprotection and myelination. Growth Horm IGF Res. 2004 Jun;14 Suppl A:S18-33. [PubMed:15135772]
  4. Hould FS, Fried GM, Fazekas AG, Tremblay S, Mersereau WA: Progesterone receptors regulate gallbladder motility. J Surg Res. 1988 Dec;45(6):505-12. [PubMed:3184927]
External Links
Human Metabolome Database
HMDB01830
KEGG Drug
D00066
KEGG Compound
C00410
PubChem Compound
5994
PubChem Substance
46508968
ChemSpider
5773
BindingDB
8903
ChEBI
17026
ChEMBL
CHEMBL103
Therapeutic Targets Database
DAP000549
PharmGKB
PA451123
HET
STR
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Progesterone
ATC Codes
G03DA04 — ProgesteroneG03FA04 — Progesterone and estrogen
AHFS Codes
  • 68:32.00 — Progestins
PDB Entries
1a28 / 1dbb / 1h60 / 1mrq / 1w0f / 1ya3 / 2aa5 / 2aa6 / 2aba / 2hzq
show 14 more
FDA label
Download (86.6 KB)
MSDS
Download (74.2 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingBasic ScienceFemale Puberty1
1Active Not RecruitingBasic ScienceFemale Reproductive Physiology1
1CompletedNot AvailableDependence, Cocaine1
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentInfertilities1
1CompletedTreatmentMenopause1
1CompletedTreatmentTobacco Use Disorders1
1RecruitingBasic ScienceHyperandrogenism / Normal Puberty / Polycystic Ovaries Syndrome1
1RecruitingOtherHyperandrogenism / Puberty1
1RecruitingOtherNormal / Polycystic Ovarian Syndrome1
1RecruitingOtherPolycystic Ovaries Syndrome1
1TerminatedTreatmentPregnancy1
1, 2CompletedTreatmentInfertilities1
1, 2CompletedTreatmentPostmenopausal Endometrium1
1, 2CompletedTreatmentTraumatic Brain Injury (TBI)1
2CompletedBasic ScienceOrthostatic Intolerance1
2CompletedPreventionPreterm Delivery1
2CompletedPreventionProlonged QT Interval in EKG and Sudden Death1
2CompletedTreatmentAlzheimer's Disease (AD)1
2CompletedTreatmentAtherosclerosis / Healthy Volunteers / Vascular Diseases1
2CompletedTreatmentBipolar Disorder (BD) / Mania / Schizoaffective Disorders1
2CompletedTreatmentCervical Intraepithelial Neoplasia (CIN)1
2CompletedTreatmentHealthy Volunteers1
2CompletedTreatmentInfertilities1
2CompletedTreatmentMenopause1
2CompletedTreatmentTobacco Use Disorders1
2Not Yet RecruitingTreatmentIVF1
2Not Yet RecruitingTreatmentInfection, Human Immunodeficiency Virus I1
2RecruitingPreventionAbortions spontaneous / Premature Births1
2RecruitingPreventionPregnancy termination therapy1
2RecruitingTreatmentBrain Development / Congenital Heart Disease (CHD) / Fetal Neuroprotection / Neurodevelopmental Disability / Periventricular Leucomalacia / Surgery, Cardiac1
2RecruitingTreatmentCardiovascular Disease (CVD) / Estrogen Deficiency / Hypothalamic Amenorrhea1
2RecruitingTreatmentMenopause1
2TerminatedTreatmentVulvar Lichen Sclerosus1
2Unknown StatusDiagnosticPremenstrual Syndrome1
2Unknown StatusPreventionPremature Labour1
2Unknown StatusTreatmentEndometrial Cancers / Endometrial Hyperplasia1
2Unknown StatusTreatmentMenopause1
2Unknown StatusTreatmentPremenstrual Syndrome1
2, 3CompletedPreventionPreterm Delivery1
2, 3CompletedTreatmentAlzheimer's Disease (AD)1
2, 3CompletedTreatmentDependence, Cocaine1
2, 3CompletedTreatmentMenopause1
2, 3Not Yet RecruitingPreventionCervical incompetence / Cervical Shortening / Premature Births / Preterm Labor With Preterm Delivery, Unspecified Trimester, Fetus 21
2, 3Not Yet RecruitingTreatmentPremature Births / Short Cervix1
2, 3RecruitingPreventionPremature Births / Twin Pregnancy With Antenatal Problem1
2, 3RecruitingTreatmentAlcohol Dependence / Post-Traumatic Stress Disorder (PTSD)1
2, 3TerminatedTreatmentComplications, Pregnancy1
2, 3Unknown StatusScreeningPreeclampsia1
3Active Not RecruitingTreatmentMenopausal Hot Flushes / Night Sweats1
3Active Not RecruitingTreatmentMenstrual Cramps / Perimenopause1
3CompletedPreventionAlzheimer's Disease (AD) / Memory Disorders1
3CompletedPreventionBone destruction / Bone Diseases / Cardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Diabetes Mellitus (DM) / Heart Diseases / Hypercholesterolaemia / Hypertensive / Myocardial Ischemia / One to five years postmenopausal / Thrombosis1
3CompletedPreventionCardiovascular Disease (CVD) / Coronary Arteriosclerosis / Coronary Heart Disease (CHD) / Heart Diseases / Myocardial Ischemia / One to five years postmenopausal1
3CompletedPreventionCardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Heart Diseases / One to five years postmenopausal / Unstable Angina (UA)1
3CompletedPreventionNeonatal Complications / Premature Births / Preterm Delivery1
3CompletedPreventionPregnancy1
3CompletedPreventionPregnancy Trimester, Second / Premature Births1
3CompletedPreventionPremature Births1
3CompletedPreventionPreterm Delivery1
3CompletedPreventionPreterm Delivery / Short Cervix / Short Uterine Cervical Length1
3CompletedTreatmentAssisted Reproductive Technology therapy4
3CompletedTreatmentBrain Injury1
3CompletedTreatmentFertility1
3CompletedTreatmentInfertilities3
3CompletedTreatmentMenopause1
3CompletedTreatmentPremature Births1
3Not Yet RecruitingTreatmentLuteal Phase Defect1
3Not Yet RecruitingTreatmentThreatened Abortion in First Trimester1
3RecruitingPreventionObstetric Labor, Premature [C13.703.420.491] / Twins, Dizygotic [M01.438.873.920]1
3RecruitingTreatmentEndometrial Polyps1
3RecruitingTreatmentEndometriosis1
3RecruitingTreatmentExercise-related Amenorrhea1
3RecruitingTreatmentInfertilities2
3RecruitingTreatmentMenopause related conditions1
3RecruitingTreatmentPrimary Ovarian Insufficiency1
3RecruitingTreatmentShort Cervical Length1
3TerminatedPreventionMorbidity / Perinatal Mortality / Preterm Delivery1
3TerminatedTreatmentSecondary Amenorrhea1
3TerminatedTreatmentTraumatic Brain Injury (TBI)1
3Unknown StatusPreventionPremature Births1
3WithdrawnTreatmentAmenorrhea / Bone Loss1
3WithdrawnTreatmentInfertilities1
4Active Not RecruitingBasic ScienceContraception / Fertility1
4CompletedPreventionContraception / Pregnancy1
4CompletedPreventionPremature Labour1
4CompletedPreventionPreterm Delivery1
4CompletedTreatmentAbortions spontaneous / Subchorionic Hematoma in the First Trimester Pregnancy1
4CompletedTreatmentConcussions1
4CompletedTreatmentFertility / Optimal Stimulation Protocol / Reproductive Endocrinology1
4CompletedTreatmentHealthy Volunteers / One to five years postmenopausal1
4CompletedTreatmentInfertilities6
4CompletedTreatmentInfertilities / Polycystic Ovarian Syndrome1
4CompletedTreatmentInfertilities / Progesterone Levels1
4CompletedTreatmentPremature Ovarian Failure (POF)1
4CompletedTreatmentRecurrent Abortion1
4CompletedTreatmentSecondary Amenorrhea1
4CompletedTreatmentThreatened Premature Labor1
4Not Yet RecruitingTreatmentInfertilities1
4RecruitingBasic SciencePerimenopausal Depression1
4RecruitingPreventionDrug-induced QT Interval Prolongation / Prolonged QT Interval in EKG and Sudden Death1
4RecruitingPreventionPremature Births1
4RecruitingPreventionPremature Labour1
4RecruitingPreventionPreterm Delivery1
4RecruitingSupportive CareAssisted Reproductive Technology therapy / Infertilities1
4RecruitingTreatmentCessation, Smoking1
4RecruitingTreatmentFrozen Embryo Transfer / Pregnancy Loss1
4RecruitingTreatmentInfertilities2
4RecruitingTreatmentNicotine Dependence / Nicotine Withdrawal1
4TerminatedTreatmentObstetric Labour, Premature1
4Unknown StatusNot AvailablePharmacogenomics / Systems Biology1
4Unknown StatusPreventionArteriosclerosis / Menopause1
4Unknown StatusPreventionPregnancy1
4Unknown StatusTreatmentCryopreservation / Implantation, Embryo / Progesteron1
4Unknown StatusTreatmentIVF - Luteal Phase Support After Embryo Transfer1
4Unknown StatusTreatmentInfertilities1
4Unknown StatusTreatmentPregnancy / Pregnancy Loss1
4Unknown StatusTreatmentProgesterone Supplementation1
4Unknown StatusTreatmentReproductive Techniques, Assisted1
Not AvailableActive Not RecruitingNot AvailableAging / One to five years postmenopausal1
Not AvailableActive Not RecruitingBasic ScienceHyperandrogenism / Polycystic Ovaries Syndrome2
Not AvailableActive Not RecruitingOtherLuteal Phase Defect1
Not AvailableCompletedNot AvailableAssisted Reproductive Technology therapy2
Not AvailableCompletedNot AvailableBMI >30 kg/m2 / Obstructive Sleep Apnea (OSA) / Polycystic Ovaries Syndrome1
Not AvailableCompletedNot AvailableHealthy Volunteers1
Not AvailableCompletedNot AvailableInfertility, Subfertility1
Not AvailableCompletedNot AvailableNeonates / Pregnancy3
Not AvailableCompletedNot AvailablePolycystic Ovarian Syndrome1
Not AvailableCompletedBasic ScienceBMI >30 kg/m2 / Infertilities1
Not AvailableCompletedBasic ScienceCoronary Heart Disease (CHD)1
Not AvailableCompletedBasic ScienceHyperandrogenemia / Polycystic Ovary Syndrome (PCOS)1
Not AvailableCompletedBasic SciencePostpartum Depression1
Not AvailableCompletedPreventionPremature Births1
Not AvailableCompletedPreventionThe Association Between Progesterone Levels and Smoking Related Symptomatology and Nicotine Cravings / The Association Between Progesterone Levels and Smoking-related Symptomatology and Nicotine Cravings1
Not AvailableCompletedPreventionTobacco Cessation1
Not AvailableCompletedPreventionTobacco Use Cessation / Tobacco Use Disorders1
Not AvailableCompletedScreeningOther Diseases or Conditions1
Not AvailableCompletedTreatmentCocaine Abuse / Cocaine-Related Disorders1
Not AvailableCompletedTreatmentCocaine Abuse / Dependence, Cocaine / Postpartum Period1
Not AvailableCompletedTreatmentFertilization in Vitro / Infertilities / Recurrent Implantation Failure (RIF)1
Not AvailableCompletedTreatmentInfants, Premature / Premature Births1
Not AvailableCompletedTreatmentInfertilities2
Not AvailableCompletedTreatmentLuteal Phase Defect1
Not AvailableCompletedTreatmentMarijuana Dependence1
Not AvailableCompletedTreatmentMenopausal and Postmenopausal Disorders1
Not AvailableCompletedTreatmentOvarian Failure, Premature1
Not AvailableCompletedTreatmentPremature Births1
Not AvailableCompletedTreatmentOne to five years postmenopausal2
Not AvailableNot Yet RecruitingOtherPremature Births / Short Cervix1
Not AvailableNot Yet RecruitingPreventionPerimenopausal Disorder / Stress, Emotional1
Not AvailableNot Yet RecruitingTreatmentPremature Labour1
Not AvailableRecruitingNot AvailableThreatened Miscarriage1
Not AvailableRecruitingBasic ScienceHyperandrogenemia / Polycystic Ovaries Syndrome1
Not AvailableRecruitingBasic ScienceMenopause1
Not AvailableRecruitingPreventionAntepartum Hemorrhage / Premature Births1
Not AvailableRecruitingPreventionPremature Births1
Not AvailableRecruitingTreatmentInfertilities / OHSS1
Not AvailableRecruitingTreatmentPregnancy1
Not AvailableRecruitingTreatmentPremature Labour1
Not AvailableRecruitingTreatmentThreatened Miscarriage1
Not AvailableSuspendedNot AvailableNicotine Dependence2
Not AvailableTerminatedPreventionPreeclampsia1
Not AvailableTerminatedTreatmentDependence, Cocaine / Nicotine Dependence1
Not AvailableTerminatedTreatmentPregnancy1
Not AvailableTerminatedTreatmentSubfertility1
Not AvailableUnknown StatusTreatmentInfertilities3
Not AvailableWithdrawnNot AvailablePregnancy / Premature Births1
Not AvailableWithdrawnPreventionIntrauterine Growth Retardation / Premature Births / Premature separation of placenta / Prophylaxis of preeclampsia / Threatened Abortion1
Not AvailableWithdrawnTreatmentPremature Labour1

Pharmacoeconomics

Manufacturers
  • Bristol myers squibb
  • Amarin pharmaceuticals inc
  • Solvay pharmaceuticals
  • Esi pharmacal
  • Unimed pharmaceuticals llc
  • Watson laboratories inc
  • App pharmaceuticals llc
  • Eli lilly and co
  • Pharmaforce inc
  • Alza corp
  • Ferring pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
SolutionIntramuscular50 mg
GelVaginal45 mg/1.125g
GelVaginal8 %
GelVaginal90 mg/1.125g
InsertVaginal100 mg/1
InsertVaginal100 mg
Capsule; gel, meteredOral; Transdermal
LiquidIntramuscular50 mg
CapsuleOral100 mg/1
CapsuleOral200 mg/1
Capsule, liquid filledOral100 mg/1
Capsule, liquid filledOral200 mg/1
InjectionIntramuscular50 mg/1
Injection, solutionIntramuscular50 mg/mL
CapsuleOral100 mg
CapsuleVaginal200 mg
Prices
Unit descriptionCostUnit
Prochieve 4% Gel (18 Applicators Per Box)160.18USD tube
Crinone 8% Gel (1 Box = 6 Applications)84.26USD box
Prochieve 8% Gel 1.45 gm Tube14.83USD tube
Crinone 8% gel13.61USD g
Prochieve 8% gel12.0USD g
Prochieve 4% gel8.56USD g
Progesterone 50 mg/ml6.6USD ml
Progesterone oil 50 mg/ml vial3.88USD ml
Prometrium 200 mg capsule3.84USD capsule
First-progesterone vgs 400 susuppositoryp3.33USD each
First-progesterone vgs 200 suppository3.15USD each
First-progesterone vgs 100 suppository3.0USD each
First-progesterone vgs 50 suppository2.93USD each
First-progesterone vgs 25 suppository2.88USD each
Prometrium 100 mg capsule1.69USD capsule
Progesterone powder micronized0.74USD g
Progesterone powder milled0.73USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5543150No1993-09-152013-09-15Us
US7300664No1999-11-172019-11-17Us
US7320800No1999-11-172019-11-17Us
US7393543No1999-11-172019-11-17Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)121 °CPhysProp
water solubility8.81 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP3.87HANSCH,C ET AL. (1995)
logS-4.43ADME Research, USCD
Caco2 permeability-4.37ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.00546 mg/mLALOGPS
logP3.58ALOGPS
logP4.15ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)18.47ChemAxon
pKa (Strongest Basic)-4.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area34.14 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity92.71 m3·mol-1ChemAxon
Polarizability37.26 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.982
Caco-2 permeable+0.7724
P-glycoprotein substrateSubstrate0.5449
P-glycoprotein inhibitor IInhibitor0.8841
P-glycoprotein inhibitor IIInhibitor0.6043
Renal organic cation transporterNon-inhibitor0.6931
CYP450 2C9 substrateNon-substrate0.847
CYP450 2D6 substrateNon-substrate0.8795
CYP450 3A4 substrateSubstrate0.7408
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9533
CYP450 2C19 inhibitorNon-inhibitor0.6514
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8203
Ames testNon AMES toxic0.9626
CarcinogenicityNon-carcinogens0.9151
BiodegradationNot ready biodegradable0.9575
Rat acute toxicity1.8041 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7451
hERG inhibition (predictor II)Non-inhibitor0.7454
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (11.5 KB)
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - GC-MSGC-MSsplash10-0fbc-5910000000-422e38df6de7e8b0a4b7
GC-MS Spectrum - GC-MSGC-MSsplash10-0fbc-5910000000-385f45345742235da8e0
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-024l-6923000000-639c7405f69825de7f90
GC-MS Spectrum - EI-BGC-MSsplash10-0229-2941000000-1e075d8489b79cf4e34a
GC-MS Spectrum - EI-BGC-MSsplash10-0229-3963000000-f35e3d9faf6b2ee87465
GC-MS Spectrum - GC-MSGC-MSsplash10-0fbc-5910000000-422e38df6de7e8b0a4b7
GC-MS Spectrum - GC-MSGC-MSsplash10-0fbc-5910000000-385f45345742235da8e0
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-0f6x-2910000000-1baafb91a3e0b988caa7
Mass Spectrum (Electron Ionization)MSsplash10-006x-7931000000-f6ad83adccd7e016fa29
MS/MS Spectrum - Quattro_QQQ 10V, PositiveLC-MS/MSsplash10-014i-1009000000-0f8b7c3e6c2265c3889f
MS/MS Spectrum - Quattro_QQQ 25V, PositiveLC-MS/MSsplash10-052b-8900000000-0b0167121b798e7e7534
MS/MS Spectrum - Quattro_QQQ 40V, PositiveLC-MS/MSsplash10-052b-9400000000-881510cbcecd9cb61f4f
MS/MS Spectrum - EI-B (JEOL JMS-01-SG-2) , PositiveLC-MS/MSsplash10-024l-6923000000-639c7405f69825de7f90
MS/MS Spectrum - EI-B (HITACHI M-52) , PositiveLC-MS/MSsplash10-0229-2941000000-1e075d8489b79cf4e34a
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00kb-7955000000-a22f06eac940cd4f753d
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014i-0139000000-6b47f75a44df3e20fa3b
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0aba-0950000000-b26d04d179294aa67cc7
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0aba-0920000000-d0a3365efe1f8a589564
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-05aj-0910000000-61d7a07e6be85600e1f1
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014i-0009000000-67c6f0147801f0ece957
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-05mk-8956000000-aa5fe992c41261b62fbf
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-052b-6910000000-5e26497eb2d0150a30ac
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4j-8900000000-7ca6fd15f0ccc18bfa31
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-052b-9700000000-523fe1ad11bfcbb46f85
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-054k-9400000000-e3d581bd8685e1d3f35d
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4j-5900000000-8a409fe2508f58822f8a
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4j-8900000000-fc9280df2a7dee451abb
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0290000000-0f9dd31ff254325dd522
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0290000000-b59a04537c8d112aa2ab
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-0002-0190000000-b5fed26f17626a75c34c
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-0002-0190000000-58920a9d93488054d8d5
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-002k-0190000000-5f1ba0db62e0ade93f30
MS/MS Spectrum - , positiveLC-MS/MSsplash10-014i-0229000000-c83c60bdf0d3b91077c9
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4j-5921000000-fccf432e6f84ed354acd
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-4921100000-41abb61d58cd1d7a0f7c
1H NMR Spectrum1D NMRNot Applicable
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Pregnane steroids
Direct Parent
Gluco/mineralocorticoids, progestogins and derivatives
Alternative Parents
20-oxosteroids / 3-oxo delta-4-steroids / Delta-4-steroids / Cyclohexenones / Organic oxides / Hydrocarbon derivatives
Substituents
Progestogin-skeleton / 20-oxosteroid / Oxosteroid / 3-oxosteroid / 3-oxo-delta-4-steroid / Delta-4-steroid / Cyclohexenone / Cyclic ketone / Ketone / Organic oxygen compound
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
3-oxo Delta(4)-steroid, 20-oxo steroid, C21-steroid hormone (CHEBI:17026) / Pregnane and derivatives [Fig], Progestagens (C00410) / C21 steroids (gluco/mineralocorticoids, progestogins) and derivatives (LMST02030159)

Targets

Details
1. Progesterone receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Progesterone receptor ...
Gene Name
PGR
Uniprot ID
P06401
Uniprot Name
Progesterone receptor
Molecular Weight
98979.96 Da
References
  1. Madauss KP, Stewart EL, Williams SP: The evolution of progesterone receptor ligands. Med Res Rev. 2007 May;27(3):374-400. [PubMed:17013809]
  2. Gizard F, Robillard R, Gross B, Barbier O, Revillion F, Peyrat JP, Torpier G, Hum DW, Staels B: TReP-132 is a novel progesterone receptor coactivator required for the inhibition of breast cancer cell growth and enhancement of differentiation by progesterone. Mol Cell Biol. 2006 Oct;26(20):7632-44. [PubMed:17015480]
  3. Wu HB, Fabian S, Jenab S, Quinones-Jenab V: Progesterone receptors activation after acute cocaine administration. Brain Res. 2006 Dec 18;1126(1):188-92. Epub 2006 Nov 15. [PubMed:17109827]
  4. Boonyaratanakornkit V, McGowan E, Sherman L, Mancini MA, Cheskis BJ, Edwards DP: The role of extranuclear signaling actions of progesterone receptor in mediating progesterone regulation of gene expression and the cell cycle. Mol Endocrinol. 2007 Feb;21(2):359-75. Epub 2006 Nov 30. [PubMed:17138644]
  5. Tranguch S, Smith DF, Dey SK: Progesterone receptor requires a co-chaperone for signalling in uterine biology and implantation. Reprod Biomed Online. 2006 Nov;13(5):651-60. [PubMed:17169175]
  6. Luconi M, Bonaccorsi L, Maggi M, Pecchioli P, Krausz C, Forti G, Baldi E: Identification and characterization of functional nongenomic progesterone receptors on human sperm membrane. J Clin Endocrinol Metab. 1998 Mar;83(3):877-85. [PubMed:9506743]
Details
2. Estrogen receptor alpha
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissu...
Gene Name
ESR1
Uniprot ID
P03372
Uniprot Name
Estrogen receptor
Molecular Weight
66215.45 Da
References
  1. Kumar AS, Cureton E, Shim V, Sakata T, Moore DH, Benz CC, Esserman LJ, Hwang ES: Type and duration of exogenous hormone use affects breast cancer histology. Ann Surg Oncol. 2007 Feb;14(2):695-703. Epub 2006 Nov 14. [PubMed:17103262]
  2. Lessey BA, Palomino WA, Apparao KB, Young SL, Lininger RA: Estrogen receptor-alpha (ER-alpha) and defects in uterine receptivity in women. Reprod Biol Endocrinol. 2006;4 Suppl 1:S9. [PubMed:17118173]
  3. Yuri T, Tsukamoto R, Uehara N, Matsuoka Y, Tsubura A: Effects of different durations of estrogen and progesterone treatment on development of N-methyl-N-nitrosourea-induced mammary carcinomas in female Lewis rats. In Vivo. 2006 Nov-Dec;20(6B):829-36. [PubMed:17203775]
  4. Montero Girard G, Vanzulli SI, Cerliani JP, Bottino MC, Bolado J, Vela J, Becu-Villalobos D, Benavides F, Gutkind S, Patel V, Molinolo A, Lanari C: Association of estrogen receptor-alpha and progesterone receptor A expression with hormonal mammary carcinogenesis: role of the host microenvironment. Breast Cancer Res. 2007;9(2):R22. [PubMed:17341305]
  5. Ghebeh H, Tulbah A, Mohammed S, Elkum N, Bin Amer SM, Al-Tweigeri T, Dermime S: Expression of B7-H1 in breast cancer patients is strongly associated with high proliferative Ki-67-expressing tumor cells. Int J Cancer. 2007 Aug 15;121(4):751-8. [PubMed:17415709]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Zinc ion binding
Specific Function
Receptor for both mineralocorticoids (MC) such as aldosterone and glucocorticoids (GC) such as corticosterone or cortisol. Binds to mineralocorticoid response elements (MRE) and transactivates targ...
Gene Name
NR3C2
Uniprot ID
P08235
Uniprot Name
Mineralocorticoid receptor
Molecular Weight
107066.575 Da
References
  1. Rupprecht R, Reul JM, van Steensel B, Spengler D, Soder M, Berning B, Holsboer F, Damm K: Pharmacological and functional characterization of human mineralocorticoid and glucocorticoid receptor ligands. Eur J Pharmacol. 1993 Oct 15;247(2):145-54. [PubMed:8282004]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid 17-alpha-monooxygenase activity
Specific Function
Conversion of pregnenolone and progesterone to their 17-alpha-hydroxylated products and subsequently to dehydroepiandrosterone (DHEA) and androstenedione. Catalyzes both the 17-alpha-hydroxylation ...
Gene Name
CYP17A1
Uniprot ID
P05093
Uniprot Name
Steroid 17-alpha-hydroxylase/17,20 lyase
Molecular Weight
57369.995 Da
References
  1. Haidar S, Hartmann RW: C16 and C17 substituted derivatives of pregnenolone and progesterone as inhibitors of 17alpha-hydroxylase-C17, 20-lyase: synthesis and biological evaluation. Arch Pharm (Weinheim). 2002;335(11-12):526-34. [PubMed:12596217]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Activator
General Function
Opioid receptor activity
Specific Function
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synt...
Gene Name
OPRK1
Uniprot ID
P41145
Uniprot Name
Kappa-type opioid receptor
Molecular Weight
42644.665 Da
References
  1. Dawson-Basoa ME, Gintzler AR: Estrogen and progesterone activate spinal kappa-opiate receptor analgesic mechanisms. Pain. 1996 Jan;64(1):169-77. [PubMed:8867260]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Nuclear receptor that binds and is activated by variety of endogenous and xenobiotic compounds. Transcription factor that activates the transcription of multiple genes involved in the metabolism an...
Gene Name
NR1I2
Uniprot ID
O75469
Uniprot Name
Nuclear receptor subfamily 1 group I member 2
Molecular Weight
49761.245 Da
References
  1. Kretschmer XC, Baldwin WS: CAR and PXR: xenosensors of endocrine disrupters? Chem Biol Interact. 2005 Aug 15;155(3):111-28. [PubMed:16054614]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Not Available
Specific Function
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in...
Gene Name
ORM1
Uniprot ID
P02763
Uniprot Name
Alpha-1-acid glycoprotein 1
Molecular Weight
23511.38 Da
References
  1. Albani JR: Progesterone binding to the tryptophan residues of human alpha1-acid glycoprotein. Carbohydr Res. 2006 Nov 6;341(15):2557-64. Epub 2006 Aug 8. [PubMed:16901474]
Details
8. Glucocorticoid receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Partial agonist
General Function
Zinc ion binding
Specific Function
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
Gene Name
NR3C1
Uniprot ID
P04150
Uniprot Name
Glucocorticoid receptor
Molecular Weight
85658.57 Da
References
  1. Attardi BJ, Zeleznik A, Simhan H, Chiao JP, Mattison DR, Caritis SN: Comparison of progesterone and glucocorticoid receptor binding and stimulation of gene expression by progesterone, 17-alpha hydroxyprogesterone caproate, and related progestins. Am J Obstet Gynecol. 2007 Dec;197(6):599.e1-7. [PubMed:18060946]
Details
9. Androgen receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription ...
Gene Name
AR
Uniprot ID
P10275
Uniprot Name
Androgen receptor
Molecular Weight
98987.9 Da
References
  1. van der Burg B, Winter R, Man HY, Vangenechten C, Berckmans P, Weimer M, Witters H, van der Linden S: Optimization and prevalidation of the in vitro AR CALUX method to test androgenic and antiandrogenic activity of compounds. Reprod Toxicol. 2010 Aug;30(1):18-24. doi: 10.1016/j.reprotox.2010.04.012. Epub 2010 May 10. [PubMed:20438827]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Androgen binding
Specific Function
Functions as an androgen transport protein, but may also be involved in receptor mediated processes. Each dimer binds one molecule of steroid. Specific for 5-alpha-dihydrotestosterone, testosterone...
Gene Name
SHBG
Uniprot ID
P04278
Uniprot Name
Sex hormone-binding globulin
Molecular Weight
43778.755 Da
References
  1. Hong H, Branham WS, Ng HW, Moland CL, Dial SL, Fang H, Perkins R, Sheehan D, Tong W: Human sex hormone-binding globulin binding affinities of 125 structurally diverse chemicals and comparison with their binding to androgen receptor, estrogen receptor, and alpha-fetoprotein. Toxicol Sci. 2015 Feb;143(2):333-48. doi: 10.1093/toxsci/kfu231. Epub 2014 Oct 27. [PubMed:25349334]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Lin Y, Lu P, Tang C, Mei Q, Sandig G, Rodrigues AD, Rushmore TH, Shou M: Substrate inhibition kinetics for cytochrome P450-catalyzed reactions. Drug Metab Dispos. 2001 Apr;29(4 Pt 1):368-74. [PubMed:11259318]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Details
2. Cytochrome P450 2C9
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid 17-alpha-monooxygenase activity
Specific Function
Conversion of pregnenolone and progesterone to their 17-alpha-hydroxylated products and subsequently to dehydroepiandrosterone (DHEA) and androstenedione. Catalyzes both the 17-alpha-hydroxylation ...
Gene Name
CYP17A1
Uniprot ID
P05093
Uniprot Name
Steroid 17-alpha-hydroxylase/17,20 lyase
Molecular Weight
57369.995 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d 24-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A1
Uniprot ID
P04798
Uniprot Name
Cytochrome P450 1A1
Molecular Weight
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1B1
Uniprot ID
Q16678
Uniprot Name
Cytochrome P450 1B1
Molecular Weight
60845.33 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Const...
Gene Name
CYP2A6
Uniprot ID
P11509
Uniprot Name
Cytochrome P450 2A6
Molecular Weight
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Romiti N, Tramonti G, Chieli E: Influence of different chemicals on MDR-1 P-glycoprotein expression and activity in the HK-2 proximal tubular cell line. Toxicol Appl Pharmacol. 2002 Sep 1;183(2):83-91. [PubMed:12387747]
  2. Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5. [PubMed:11716514]
  3. Leonessa F, Kim JH, Ghiorghis A, Kulawiec RJ, Hammer C, Talebian A, Clarke R: C-7 analogues of progesterone as potent inhibitors of the P-glycoprotein efflux pump. J Med Chem. 2002 Jan 17;45(2):390-8. [PubMed:11784143]
  4. Ueda K, Okamura N, Hirai M, Tanigawara Y, Saeki T, Kioka N, Komano T, Hori R: Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem. 1992 Dec 5;267(34):24248-52. [PubMed:1360010]
  5. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. [PubMed:14985103]
  6. Yamazaki M, Neway WE, Ohe T, Chen I, Rowe JF, Hochman JH, Chiba M, Lin JH: In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results. J Pharmacol Exp Ther. 2001 Mar;296(3):723-35. [PubMed:11181899]
  7. Adachi Y, Suzuki H, Sugiyama Y: Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8. [PubMed:11785684]
  8. Borgnia MJ, Eytan GD, Assaraf YG: Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity. J Biol Chem. 1996 Feb 9;271(6):3163-71. [PubMed:8621716]
  9. Kim WY, Benet LZ: P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm Res. 2004 Jul;21(7):1284-93. [PubMed:15290871]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Quaternary ammonium group transmembrane transporter activity
Specific Function
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creat...
Gene Name
SLC22A2
Uniprot ID
O15244
Uniprot Name
Solute carrier family 22 member 2
Molecular Weight
62579.99 Da
References
  1. Hayer-Zillgen M, Bruss M, Bonisch H: Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol. 2002 Jul;136(6):829-36. [PubMed:12110607]
  2. Wu X, Kekuda R, Huang W, Fei YJ, Leibach FH, Chen J, Conway SJ, Ganapathy V: Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain. J Biol Chem. 1998 Dec 4;273(49):32776-86. [PubMed:9830022]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Secondary active organic cation transmembrane transporter activity
Specific Function
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnico...
Gene Name
SLC22A1
Uniprot ID
O15245
Uniprot Name
Solute carrier family 22 member 1
Molecular Weight
61153.345 Da
References
  1. Hayer-Zillgen M, Bruss M, Bonisch H: Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol. 2002 Jul;136(6):829-36. [PubMed:12110607]
  2. Wu X, Kekuda R, Huang W, Fei YJ, Leibach FH, Chen J, Conway SJ, Ganapathy V: Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain. J Biol Chem. 1998 Dec 4;273(49):32776-86. [PubMed:9830022]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Toxin transporter activity
Specific Function
Mediates potential-dependent transport of a variety of organic cations. May play a significant role in the disposition of cationic neurotoxins and neurotransmitters in the brain.
Gene Name
SLC22A3
Uniprot ID
O75751
Uniprot Name
Solute carrier family 22 member 3
Molecular Weight
61279.485 Da
References
  1. Hayer-Zillgen M, Bruss M, Bonisch H: Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol. 2002 Jul;136(6):829-36. [PubMed:12110607]
  2. Wu X, Kekuda R, Huang W, Fei YJ, Leibach FH, Chen J, Conway SJ, Ganapathy V: Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain. J Biol Chem. 1998 Dec 4;273(49):32776-86. [PubMed:9830022]
Details
5. Bile salt export pump
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Transporter activity
Specific Function
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name
ABCB11
Uniprot ID
O95342
Uniprot Name
Bile salt export pump
Molecular Weight
146405.83 Da
References
  1. Wang EJ, Casciano CN, Clement RP, Johnson WW: Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites. Pharm Res. 2003 Apr;20(4):537-44. [PubMed:12739759]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Transporter activity
Specific Function
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotre...
Gene Name
ABCC1
Uniprot ID
P33527
Uniprot Name
Multidrug resistance-associated protein 1
Molecular Weight
171589.5 Da
References
  1. Payen L, Delugin L, Courtois A, Trinquart Y, Guillouzo A, Fardel O: Reversal of MRP-mediated multidrug resistance in human lung cancer cells by the antiprogestatin drug RU486. Biochem Biophys Res Commun. 1999 May 19;258(3):513-8. [PubMed:10329417]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Virus receptor activity
Specific Function
The hepatic sodium/bile acid uptake system exhibits broad substrate specificity and transports various non-bile acid organic compounds as well. It is strictly dependent on the extracellular presenc...
Gene Name
SLC10A1
Uniprot ID
Q14973
Uniprot Name
Sodium/bile acid cotransporter
Molecular Weight
38118.64 Da
References
  1. Schroeder A, Eckhardt U, Stieger B, Tynes R, Schteingart CD, Hofmann AF, Meier PJ, Hagenbuch B: Substrate specificity of the rat liver Na(+)-bile salt cotransporter in Xenopus laevis oocytes and in CHO cells. Am J Physiol. 1998 Feb;274(2 Pt 1):G370-5. [PubMed:9486191]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:34